tbuckley/cabot-search huggingface dataset:
Clofibrate and niacin in coronary heart disease
Journal: JAMA (1975)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Blood Alcohol
Authors: Esteban Mezey
Journal: JAMA (1974)

<h3>To the Editor.—</h3> The report of unusually high ethanol levels in a living patient by Hammond et al (226:63, 1973) is indeed remarkable because of the degree of tolerance that the patient exhibited to such high concentrations. However, the explanation of the exponential disappearance of the ethanol in this patient on the basis of induction of the hepatic ethanolmetabolizing enzymes is difficult to accept. There was an extremely rapid initial disappearance of ethanol from the blood in the first six hours, from a level of 780 mg/100 ml to about 200 mg/100 ml, approximately 97 mg/100 ml/hr. This rapid disappearance is well beyond known capabilities of the hepatic ethanol-metabolizing enzymes to oxidize ethanol<sup>1-4</sup> More likely, the initial rapid disappearance of ethanol from the blood was due to loss from the gastrointestinal tract<sup>5</sup>and urine because of therapeutic measures used, namely gastric lavage followed by instillation of charcoal, and diuresis
The summary or abstract
Authors: C. G. Roland
Journal: JAMA (1968)

There is no intrinsic difference between a well-prepared summary and an abstract. Indeed, the<i>Oxford English Dictionary</i>defines<i>abstract as</i>"a summary or epitome of a statement or document," and a<i>summary</i>of a statement is one "containing or comprising the chief points or the sum and substance of a matter." Thus if an editor asks you to prepare a summary, or an abstract, or a synopsis-abstract, you should in each case arrive at the same product. Of course, the abstract and the summary have different uses. Separate publication of abstracts provides a means of rapidly distributing information to large audiences, and this type of publication has become increasingly popular and important in the past 20 years. Although abstracting services often write abstracts, it is probably better to have the author do so himself. During the past decade more and more journals have adopted the practice of publishing a summary
Chapter 3---Summary
Journal: Gut (2000)

In chapter 3, attention has been concentrated on the interrelationships between the enteric nervous system (ENS) and the sympathetic and parasympathetic systems, which transmit signals to the central nervous system (CNS).While up until now the ENS has been regarded as virtually autonomous-as a "little" or "second" brain which influences the gut locally-the evidence to substantiate this is based on inconclusive premises.The evidence presented in this session challenges this view and demonstrates considerable connection and interplay between the ENS and CNS.Recent tracer and electrophysiological studies have shown, independently, that vagal eVerents ramify exten-
THE GREAT UNREADY" VACCINATION COMMISSION.
Journal: JAMA (1896)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Fatty Acid Metabolism in Cystic Fibrosis
Authors: Birgitta Strandvik
Journal: New England Journal of Medicine (2004)

In 1989, when the gene locus for cystic fibrosis was identified, expectations were great for rapid progress in understanding and effectively treating the disease. It was generally believed that cystic fibrosis was a monogenic disease, which would possibly soon be treatable by gene therapy. Now, 15 years later, it has turned out that nature is much more complicated than we had predicted. For example, even though more than 1200 mutations have been identified in the cystic fibrosis transmembrane conductance regulator gene (CFTR), the search for a relation between the different phenotypes and mutations has mainly failed. Furthermore, siblings . . .
Body composition and physiologic function of athletes
Authors: L. P. Novak
Journal: JAMA (1968)

Investigations which would combine body composition and cardiopulmonary function into a unified evaluation of the problems of maximal performance are very few, and those few are limited in scope and in selection of subjects. Kohlrausch<sup>1</sup>measured anthropometrically a few Olympic athletes in Amsterdam in 1928. Cureton<sup>2</sup>provided physiologic and anthropometric data of American track and field athletes in 1948. The study contributing most to understanding of the relationship of body build to performance of Olympic athletes was done by Tanner<sup>3</sup>who anthropometrically measured and made x-ray films of more than 200 athletes in 1958; subsequently, in 1960, he studied an additional 137 athletes. Tanner's pioneering work added greatly to the knowledge of body build vis-à-vis body mechanics, but he did not determine physiologic parameters or perform detailed analyses of body composition. The relationship of body composition to oxygen consumption in normal young men during submaximal work was
Abstract 2536: O-GlcNAcylation of Ewing sarcoma EWSR1/FLI1 protein impairs relocation of Aurora B to the midzone during mitosis
Authors: Mizuki Azuma
Journal: Cancer Research (2019)

Abstract Ewing sarcoma is a pediatric bone cancer expressing chimeric EWSR1/FLI1 protein derived from a t(22;11)(q24;12) translocation. Our previous study demonstrated that EWSR1/FLI1 impairs the relocation of Aurora B kinase from the centromere to the midzone during the metaphase-anaphase transition (referred to as “Aurora B-relocation”). Aurora B-relocation to the midzone is essential for faithful cell division, whereas compromising this process will lead to formation of a binucleated cell or chromosomal mis-segregation. This cellular activity might play a role in the pathogenesis of Ewing sarcoma; however, how EWSR1/FLI1 impairs Aurora B-relocation remains unclear. In the present study, we tested the hypothesis that O-GlcNAcylation of EWSR1/FLI1 impairs Aurora B-relocation. The results showed that the increase in cellular O-GlcNAc levels in Ewing sarcoma A673 cells induced by treatment with the O-GlcNAcase inhibitor Thiamet-G (TMG) increased the level of aberrant Aurora B-relocation, and the O-GlcNAcylation level of endogenously expressed EWSR1/FLI1. To map the amino acid(s) required for O-GlcNAcylation of EWSR1/FLI1, HeLa cells were used because they do not express EWSR1/FLI1 endogenously. Among the putative point mutant constructs of EWSR1/FLI1, the substitution of Thr79 of EWSR1/FLI1 by Asp (phosphor mimic mutant) significantly reduced the O-GlcNAcylation level of EWSR1/FLI1, suggesting that Thr79 is the site of O-GlcNAcylation. Finally, the EWSR1/FLI1-T79D and EWSR1/FLI1-T79A mutant constructs failed to induce aberrant Aurora B-relocation in HeLa and A673 cells. Therefore, we propose that O-GlcNAcylated EWSR1/FLI1-T79 is required for the induction of aberrant Aurora B-relocation. In addition, EWSR1/FLI1-dependent disruption of Aurora B-relocation leads to defects in chromosome instability (CIN). Here, we demonstrate a unique role of EWSR1/FLI1 that may be a part of the pathogenesis of Ewing sarcoma. Citation Format: Mizuki Azuma. O-GlcNAcylation of Ewing sarcoma EWSR1/FLI1 protein impairs relocation of Aurora B to the midzone during mitosis [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 2536.
Bilirubin conjugate changes in the bile of gallbladders containing gallstones*1
Authors: C GORESKY
Journal: Hepatology (1995)

Gallbladder bile was obtained at laparoscopic cholecystectomy from 31 patients with gallstones, and duodenal aspirates from 18 normal controls. Bile pigments (9 conjugates and unconjugated bilirubin) were analyzed by high-performance liquid chromatography. The average proportional composition of the bile pigments from the patients with gallstones was characteristically different from the controls. Whereas the average values for the principal conjugates in the controls were bilirubin diglucuronide 83.4%, bifirubin monoglucuronide 10.1%, bifirubin monoglucuronide monoglucoside 4.5%, and bilirubin monoglucuronide monoxyloside 1.0%, the corresponding values in the biles from the patients with gallstones were 66.3%, 20.6%, 6.5%, and 2.8%, respectively. Values from the more minor conjugates and unconjugated bilirubin were less than 2% in either data set. In samples obtained in 9 of the gallstone patients early and late in the procedure, no significant change was found. Over the spectrum of findings in the gallstone patients, as the proportion of bilirubin diglucuronide became smaller, that of bilirubin monoglucuronide increased substantially, whereas those of bilirubin monoglucuronide monoglucoside and bilirubin monoglucuronide monoxyloside increased to a small extent. The findings suggest that bilirubin diglucuronide hydrolysis occurs in the gallbladder bile of gallstone patients, with the production of bilirubin monoglucuronide, and that if further hydrolysis of bilirubin monoglucuronide occurs with the formation of unconjugated bilirubin, the latter does not ordinarily increase because it is being absorbed. Stasis with increased gallbladder residence time was likely present in some of the patients. The hydrolytic activity is hypothesized to arise from the gallbladder wall, or the process to be spontaneous, and its effects to be amplified by any increase in gallbladder residence time.
Lehrbuch der Differentialdiagnose innerer Krankheiten.
Journal: JAMA (1921)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
THE MEDICAL SITUATION IN RUSSIA.
Journal: JAMA (1905)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Oxidized Low Density Lipoproteins in Atherogenesis: Role of Dietary Modification
Authors: P. D. Reaven
Journal: Annual Review of Nutrition (1996)

The development of atherosclerosis is a complex and multistep process. There are many determinants in the pathogenesis of this condition, with different factors presumably playing key roles at different times in the evolution of the atherosclerotic plaque. It has been suggested that oxidation of low density lipoproteins (LDL) by cells in the artery wall leads to a proatherogenic particle that may help initiate early lesion formation. For this reason, understanding the determinants of LDL susceptibility to oxidation is essential for developing therapeutic strategies to inhibit this process. Oxidation of LDL begins with the abstraction of hydrogen from polyunsaturated fatty acids; thus, LDL fatty acid composition undoubtedly contributes to the process of LDL oxidation. Since dietary fatty acids influence the fatty acid composition of LDL and cell membranes, the amount and type of fat in the diet may effect susceptibility of LDL and cells to oxidative damage. Additionally, since cell membrane fatty acid composition also influences cellular formation of reactive oxygen species, dietary fatty acids may help determine the prooxidant activity of artery wall cells. Both cells and lipoproteins contain a variety of antioxidants that provide protection against oxidative stress. A major source of these antioxidants is the diet. Enrichment of the diet with foods high in such antioxidants as vitamin E, β-carotene. or vitamin C, or supplementation of the diet with antioxidant vitamins, may inhibit oxidation and the process of atherosclerosis.
Abstract 5093: Genome wide DNA copy number analysis of serous type ovarian carcinomas identifies genetic markers predictive of clinical outcome
Authors: David Engler, Sumeet Gupta, Whitfield Growdan, Ronny Drapkin, Mai Nitta, Petra Sergent, Serena Allred, Jenny Gross, Michael Deavers, Wen-Lin Kuo, Beth Karlan, Bo Rueda, Sandra Orsulic, David Gershenson, Michael Birrer, Joe Gray, Gayatry Mohapatra
Journal: Cancer Research (2012)

Abstract Ovarian cancer is the fifth leading cause of cancer death in women. Ovarian cancers display a high degree of complex genetic alterations involving many oncogenes and tumor suppressor genes. Analysis of the association between genetic alterations and clinical endpoints such as survival will lead to improved patient management via genetic stratification of patients into clinically relevant subgroups. In this study, we aim to define subgroups of high-grade serous ovarian carcinomas that differ with respect to prognosis and overall survival. Genome-wide DNA copy number alterations (CNAs) were measured in 72 clinically annotated, high-grade serous tumors using high-resolution oligonucleotide arrays. Two clinically annotated, independent cohorts were used as validation sets. Unsupervised hierarchical clustering of copy number data resulted in two clusters with significant difference in progression free survival (PFS) and marginal difference in overall survival (OS). GISTIC analysis of the two clusters identified altered regions unique to each cluster. Supervised clustering of two independent large cohorts of high-grade serous tumors using the classification scheme derived from the two initial clusters validated our results and identified 8 genomic regions that are distinctly different among the subgroups. These 8 regions map to 8p21.3, 8p23.2, 12p12.1, 17p11.2, 17p12, 19q12, 20q11.21 and 20q13.12; and harbor potential oncogenes and tumor suppressor genes that are likely to be involved in the pathogenesis of ovarian carcinoma. We have identified a set of genetic alterations that could be used for stratification of high-grade serous tumors into clinically relevant treatment subgroups. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 5093. doi:1538-7445.AM2012-5093
Very severe aplastic anemia following resection of lymphocytic thymoma: Effectiveness of antilymphocyte globulin, cyclosporin A, and granulocyte‐colony stimulating factor
Authors: Günçağ Dinçol, Bülent Saka, Melih Aktan, Meliha Nalçacı, Hüseyin Keskin, Şükrü Palanduz, Şükrü Öztürk, Koray Dinçol
Journal: American Journal of Hematology (2000)
Firearm-Related Years of Potential Life Lost Before Age 65 Years—United States, 1980-1991
Journal: JAMA (1994)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Book Review Euthanasia Is Not the Answer: A Hospice Physician's View By David Cundiff. 190 pp. Totowa, N.J., Humana Press, 1992. $17.95. 0-89603-237-X A Good Death: Taking More Control at the End of Your Life (A Merloyd Lawrence Book.) by Choice in Dying, T. Patrick Hill, and David Shirley. 160 pp. Reading, Mass., Addison-Wesley, 1992. $11.95. 0-201-06223-2 The Right to Die: Policy Innovation and Its Consequences By Henry R. Glick. 238 pp. New York, Columbia University Press, 1992. $32.50. 0-…
Authors: Christine Cassell
Journal: New England Journal of Medicine (1993)
Brain Serotonin Neurotoxicity and Fenfluramine and Dexfenfluramine
Authors: James P. O'Callaghan
Journal: JAMA (1997)

<h3>To the Editor.</h3> —In their review, Dr McCann and colleagues<sup>1</sup>conclude that fenfluramines damage brain serotonin neurons. They define serotonin neurotoxicity as "axotomy (ie, preterminal axon loss) of serotonin neurons in the central nervous system." Nowhere in their review do they provide evidence that fenfluramines do in fact cause axotomy; rather, they cite studies documenting what already is widely known: administration of high dosages of fenfluramines to experimental animals redices forebrain serotonin and associated markers. Decrements in serotonin markers cannot be equated with damage to serotonin neurons in the absence of evidence for underlying neuropathology. The presence of gliosis constitutes 1 such index of neuropathology. In our studies,<sup>2.3</sup>in which we observed 15% to 70% decrements in brain serotonin following high-dose dexfenfluramine regimens, we did not observe increases in the content of glial fibrillary acidic protein (GF AP), a biomarker of gliosis. Contrary to the suggestions of McCann et al, our
HIV screening and counseling for intravenous drug abuse patients. Staff and patient attitudes
Authors: J. L. Curtis
Journal: JAMA (1989)

At least one third of patients enrolled in a methadone maintenance treatment program are willing to comply voluntarily with screening for and counseling about human immunodeficiency virus (HIV). A questionnaire about knowledge, attitudes, and behavior concerning acquired immunodeficiency syndrome was answered anonymously by 79% (46) of the clinical staff and 67% (868) of the enrolled patients. On their own initiative, 21% of the patients had already received voluntary anonymous HIV screening and brief counseling, seldom discussing the result with the staff. Approximately 90% of the staff and a majority of the patients (72%) thought a voluntary HIV screening program should be offered to all patients. Almost all staff (98%), but only 50% of the patients, felt the HIV test results should be known to physicians, nurses, and counselors at the clinic. Few staff members (15%) believed that patients had changed their sex behavior; more (48%) felt that needle sharing was reduced. Patients believed methadone patients in general had changed their sex behavior (49.2%) and reduced needle sharing (62%) to prevent becoming infected. Patients reported statistically significant reductions both in number of sex partners and in personal needle sharing during the past year. (<i>JAMA</i>1989;261:258-262)